Gut microbiota may help predict which patients with type 2 diabetes will respond to the anti-diabetic drug Acarbose
15 Jan 2018by Andreu Prados
A new multicentre, randomised controlled clinical trial, led by Prof. Weiqing Wang from the Shanghai National Research Centre for Endocrine and Metabolic Diseases at the Shanghai Jiaotong University School of Medicine in Shanghai (China), has found that gut microbiota may help predict which patients with T2D respond to treatment with Acarbose.